Recent developments include the Q2 2026 earnings call and report of a Q2 loss with revenue miss, Q1 2026 earnings transcript and report of Q1 loss with revenue beat, and ongoing clinical trial progress updates.

• Fulgent Genetics held its Q2 2026 earnings call highlighting operational and clinical development updates [N1].
• The company reported a Q2 2026 net loss and missed revenue expectations [N2].
• Q1 2026 earnings transcript detailed financial results and clinical progress [N3].
• Fulgent Genetics reported a Q1 2026 loss but revenue exceeded expectations [N4].

Fulgent Genetics benefits from a diversified business model combining laboratory services with therapeutic development, leveraging proprietary technology and AI to offer a broad and scalable testing menu. The company's nano-drug delivery platform has demonstrated preliminary clinical activity and manageable safety profiles in ongoing trials, with potential to address unmet needs in cancer treatment. The strong patent portfolio and ongoing clinical programs may support future product development. The company's strong liquidity and active capital management, including stock repurchases, provide financial flexibility to support growth initiatives and clinical development.

Fulgent Genetics faces significant competition from larger, more established diagnostic and therapeutic companies with greater resources, brand recognition, and market penetration. The company relies on limited suppliers for key reagents and equipment, which could disrupt operations if supply issues arise. The ongoing transition of its billing and revenue cycle management system has caused collection delays, potentially impacting liquidity. Clinical development programs carry inherent risks including trial outcomes and regulatory challenges. The company's net losses and cash usage in operations highlight ongoing profitability and cash flow challenges.

Fulgent Genetics' moat is supported by its proprietary technology platform encompassing gene probes, AI learning software, and laboratory information management systems that enable a broad and scalable test menu with high efficiency and lower costs. Its investment in digital pathology and AI enhances diagnostic accuracy and throughput. The company's nano-drug delivery platform and associated patent portfolio provide intellectual property protection and differentiation in therapeutic development. The combination of a broad testing menu, proprietary technology, and ongoing clinical development efforts creates barriers to entry. However, the company operates in highly competitive markets with established players possessing greater resources and brand recognition, which may challenge its competitive position.

• Competitive Pressure: The company operates in highly competitive markets with numerous established and emerging players that have greater financial, technological, and marketing resources, which may limit Fulgent's market share and pricing power.
• Supply Chain Dependence: Fulgent relies on a limited number of suppliers for critical laboratory reagents and equipment, including sole suppliers for certain sequencers and maintenance services, which could disrupt operations if supply issues occur.
• Clinical Development Risks: The therapeutic development segment's clinical trials carry risks related to safety, efficacy, regulatory approval, and timing, which could affect the advancement of product candidates.
• Billing System Transition: The ongoing transition of the billing and revenue cycle management system has caused processing delays and collection issues, which may impact cash flow and financial results until fully resolved.
• Financial Performance and Liquidity: The company reported net losses and negative operating cash flow, reflecting ongoing investment in clinical development and business growth, which may require additional capital raising and impact shareholder dilution.

• Fulgent Genetics, Inc. operates a technology-based business with two main segments: laboratory services and therapeutic development (S1).
• The laboratory services business includes technical laboratory and testing services and professional interpretation by licensed physicians (S1).
• Testing services cover comprehensive anatomic pathology and precision diagnostics including next-generation sequencing (NGS) and specialized oncology services (S1).
• The company has CLIA-licensed laboratories in the U.S. and invests in digital pathology using AI technology (S1).
• Fulgent offers BioPharma services including testing and licensing to pharmaceutical, biotech companies, and CROs (S1).
• The company has a proprietary technology platform including gene probes, AI learning software, and laboratory information management systems to support test menu breadth and efficiency (S1).
• Fulgent Pharma, acquired in 2022, focuses on developing nano-drug delivery product candidates for cancer treatment using a novel nanoencapsulation platform (S1).
• Nano-drug delivery platform allows encapsulation of water insoluble or poorly soluble drugs with advantages in formulation and pharmacokinetics (S1).
• Clinical development includes Phase 1/1b and Phase 2 trials for FID-007 (nanoencapsulated paclitaxel) targeting various cancers, with preliminary data showing manageable safety and anti-tumor activity (S1).
• FID-022 (nanoencapsulated SN38) is in Phase 1/1b clinical trial with dose escalation ongoing (S1).
• The company is advancing antibody drug conjugates (ADCs) in pre-clinical development using proprietary linker and payload technology (S1).
• Customers in laboratory services are classified by payor types: insurance, institutional, and direct-pay patients (S1).
• One customer accounted for 22% of total revenue in both 2024 and 2025 (S1).
• Sales and marketing include internal teams and U.S. field-based representatives with industry experience (S1).
• Research and development includes bioinformatics, genetics, software engineering, AI R&D, and laboratory management teams (S1).
• The company launched Ultra Rapid Whole Genome Sequencing service in 2025 (S1).
• Fulgent relies on limited suppliers for key reagents and equipment, including Illumina for sequencers and Roche, Leica, Abbott for other lab equipment (S1).
• Competition includes many established and emerging companies in pathology, genetic, and diagnostic testing, as well as drug delivery and cancer therapeutics developers (S1).
• The company holds over 20 issued or allowed patents and over 10 active patent applications related to its nano-drug delivery platform, with patent protection extending to 2034 and beyond (S1).
• As of June 30, 2026, cash and cash equivalents were $26.3 million, current assets $454.8 million, current liabilities $71.8 million, with a current ratio of 6.34 and cash ratio of 0.74 (S2).
• Net income for the six months ended June 30, 2026 was a loss of $29.5 million (S2).
• Operating cash flow used $16.7 million in the six months ended June 30, 2026, less than the $34.6 million used in the prior year period (S2).
• Investing activities provided $61.7 million in cash, mainly from maturities and sales of marketable securities, partially offset by acquisitions and capital expenditures (S2).
• Financing activities used $69.1 million, primarily for common stock repurchases (S2).
• The company has a $250 million stock repurchase program authorized in March 2022 with $75.8 million remaining as of June 30, 2026 (S2).
• The company is transitioning its billing and revenue cycle management system, which has caused processing delays affecting collections (S2).
• The company does not expect to use credit facilities due to a strong cash position as of June 30, 2026 (S2).
• Recent news highlights include Q2 2026 earnings call and report of Q2 loss and revenue miss, Q1 2026 earnings transcript and report of Q1 loss with revenue beat, and ongoing clinical trial updates (N1, N2, N3, N4).